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Abstract: Lung neuroendocrine tumors are a heterogeneous sub-
type of pulmonary cancers representing approximately 20% of all 
lung cancers, including small-cell lung cancer (SCLC) and large-cell 
neuroendocrine carcinoma (LCNEC). The frequency appears to be 
approximately 3% for LCNEC. Diagnosis of LCNEC requires atten-
tion to neuroendocrine features by light microscopy and confirmation 
by immunohistochemical staining for neuroendocrine markers. Both 
SCLC and pulmonary LCNEC are high-grade and poor-prognosis 
tumors, with higher incidence in males and smokers and peripheral 
localization. LCNEC is very rare, and the precise diagnosis on small 
specimens is very difficult, so we have still too few data to define 
a standard of treatment for pulmonary LCNECs. Data of literature, 
most based on retrospective analysis, indicated a poor 5-year overall 
survival, with a high incidence of recurrence after surgery, even in 
stage I disease. Primary surgery should be the first option in all oper-
able patients because there is no validate therapeutic approach for 
LCNEC due to lack of clinical trials in this setting. Neoadjuvant plat-
inum-based regimens remain only an option for potentially resect-
able tumors. In advanced stages, SCLC-like chemotherapy seems 
the best option of treatment, with a good response rate but a poor 
overall survival (from 8 to 16 months in different case series). New 
agents are under clinical investigation to improve LCNEC patients’ 
outcome. We reviewed all data on treatment options feasible for pul-
monary LCNEC, both for localized and extensive disease.
Key Words: Lung neuroendocrine tumors, Large-cell neuroendo-
crine carcinoma, Pathologic characterization, Cancer treatment.
(J Thorac Oncol. 2015;10: 1133–1141)
Lung neuroendocrine tumors are a heterogeneous group of cancers originating from neuroendocrine cells in the 
pulmonary and bronchial epithelium and represent 20% of all 
lung cancers.1
In the 1970s, pulmonary neuroendocrine tumors were 
classified into three histologically defined categories: typi-
cal carcinoids (TC), atypical carcinoids (AC), usually defined 
as carcinoids, and the more undifferentiated entity represented 
by small-cell lung cancer (SCLC).2 In 1991, Travis et al. intro-
duced a new distinct category of lung cancer, defined as large-
cell neuroendocrine carcinoma (LCNEC), which showed large 
cells with abundant cytoplasm, necrotic areas, a high mitotic 
rate, and neuroendocrine features. It shared some characteristics 
with SCLC, while differing because this latter presents smaller 
cells, with low nuclear/cytoplasm ratio and a different pattern of 
tissue invasiveness.3 Later in 1999 and 2004, the World Health 
Organization recognizes LCNEC as a variant of large cell carci-
noma (LCC), a type of non–small-cell lung cancer (NSCLC) and 
one of the four major types of lung neuroendocrine tumors.4–6
Currently, LCNECs are considered as a separate entity 
for clinical characteristics, histology, prognosis, and survival.
INCIDENCE AND EPIDEMIOLOGY
Pulmonary LCNECs are rare tumors of the lung: in a 
series of surgically resected cases, the incidence of pulmonary 
LCNECs appeared to be between 2.1% and 3.5%. However, 
the frequency appears to be higher than estimated because of 
difficulties in diagnosis on cytological specimens.7
Unlike TCs and ACs, LCNECs are often associated with 
male sex, older age (median age is 65 years), and heavy smok-
ing habit8–11 (Table 1).
CLINICAL PRESENTATION
Several characteristics differentiate LCNECs from carci-
noids (TCs and ATs), indicating a more aggressive behavior. 
Patients with LCNECs are poorly symptomatic; cough, hemop-
tysis, or postobstructive pneumonia are infrequent. Sometimes, 
patients present an asymptomatic nodule or chest pain, nonspe-
cific flu-like symptoms, dyspnea, night sweats, and carcinoid 
syndrome. Paraneoplastic syndromes are quite uncommon. At 
the moment of diagnosis, among pulmonary neuroendocrine 
tumors, LCNEC present high rate of lymph node (60%–80%) 
and distant metastasis (40%), similar to SCLC8 (Table 1).
DIAGNOSIS AND STAGING
Diagnosis of LCNEC could be suggested by con-
ventional radiograph of the chest and computed tomog-
raphy scan. There are no specific findings in conventional 
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radiographic examination; LCNECs often are peripherally 
located expansively growing lesions with irregular margins, 
with unspecific calcifications in 10%.12 Bronchoscopy and 
staging are recommended. International Association for the 
Study of Lung Cancer suggested application of tumor, node, 
metastasis (TNM) staging to predict prognosis for neuroen-
docrine tumors.13
Because neuroendocrine tumors frequently express 
somatostatin receptors (SSTR), mostly type 2 (68%),14 
SSTR scintigraphy diagnostic techniques have been used for 
their imaging work-up. In particular, OctreoScan (indium 
11-tagged diethylenetriaminepentaacetic acid pentreotide 
scintigraphy) targets with high-affinity SSTR2, SSTR3, and 
SSTR5, whereas 111In-DOTA-TOC (111In-DOTA-DPhe1-
Tyr3-octreotide) and 111In-DOTA-LAN (111In-DOTA-
lanreotide) targets, especially, with SSTR2 and SSTR5. 
These imaging procedures have been proposed to be used 
in preoperative staging and in postoperative follow-up of 
LCNEC, but there is still no evidence supporting their use 
in clinical practice, as it is for F-18 fluorodeoxyglucose 
positron emission tomography imaging, which is still con-
troversial. Indeed, in neuroendocrine tumors, F-18 fluorode-
oxyglucose positron emission tomography can have a minor 
sensitivity than 111In-DOTA-TOC and 111In-DOTA-LAN 
in detecting metastatic lesions, expecially for those located 
in mediastinum.15
Pulmonary LCNECs diagnosis often requires immuno-
histochemical staining and sometimes electronic microscopy 
to identify clear marks of neuroendocrine differentiation, 
which are difficult to perform on small biopsies or cytology 
specimens. Consequently, diagnosis is rarely enunciated with-
out surgery.5
PATHOLOGIC CHARACTERIZATION
Histologic features of pulmonary LCNEC include large 
cell size (similar to three or more lymphocytes), areas of abun-
dant necrosis, low nuclear/cytoplasm ratio, neuroendocrine 
differentiation growth pattern such organoid nests, trabecular, 
rosette and palisading features, a variably granular pattern of 
chromatin, clear or atypical nucleoli, and high mitotic rate (11 
or more mitoses per 10 high-power fields)16–19 (Table 1).
Foci of squamous or adenomatous differentiation some-
times coexist in these tumors, creating mixed pathologic enti-
ties called “mixed LCNEC.” Although prospective data seem 
to be uncertain, mixed LCNEC exhibit an aggressive behav-
ior, with a 5-year overall survival (OS) of 30%, quite similar 
to “pure LCNEC.”20
LCNEC and AC share some pathologic features, such 
as growth patterns and necrosis, so differential diagnosis 
may be challenging. For instance, AC presents fewer mitotic 
figures and LCNEC exhibit much more necrosis.18 Indeed, a 
mitotic rate of 11 mitoses or more per 10 high-power fields 
is a key factor to differentiate LCNEC and SCLC from AC.21 
Moreover, with respect to basaloid carcinoma, it presents 
more often comedo-like necrosis compared with the abundant 
one of LCNEC, and in addition, it does not express generally 
neuroendocrine markers.18
To achieve a more precise diagnosis, a careful patho-
logic review is recommended because it is quite easy to mis-
take an LCNEC for a poorly differentiated NSCLC, an AC and 
even an SCLC. The diagnosis of LCNEC is difficult on small 
biopsy or cytological samples and often described as non–
small-cell lung carcinomas-not otherwise specified: these two 
terms referred to two different entities, not interchangeable 
expecially for treatment.22
TABLE 1.  Main Clinicopathologic Characteristics of 
Pulmonary LCNECsa
Sex Primarily in male patients (M:F = 17:1)
Median age (yr) Older (median age, 65 yr)
Smoking status Heavy smokers
Incidence 2.1%–3.5% (in surgically resected cases)
Five-year and median survival
  Resectable stage I, % 33
  Stage II, % 23
  Stage III, % 8
  Stage IV (median survival 
months)
9.2–12.6
Symptoms
  Infrequent Cough
Hemoptysis
Postobstructive pneumonia
  Sporadic Asymptomatic nodule
Chest pain
Dyspnea
Night sweats
Carcinoid syndrome
  Uncommon Paraneoplastic syndromes
Lung location Peripheral or midzone
Differentiation grade High
Neuroendocrine markers Chromogranin A
Neuron-specific enolase
Synaptophysin
Somatostatin
Mitotic count per 2 mm² field >11 mitoses/10 high power field
Necrosis Extensive
Cell histology Large cells
Low nuclear/cytoplasm ratio
Significant nuclear pleomorphism
Atypical nucleoli
Growth pattern Organoid growth pattern
Extensive areas of necrosis
Cellular palisading pattern or  
rosette-like areas
Lymphatic metastases at diagnosis 60%–80%
Distant metastases at diagnosis 40%
Treatment Surgery and neoadjuvant or adjuvant 
chemotherapy and/or RT for early 
stages (I to II)
Multimodal treatment (stage III)¹
Chemotherapy for advanced stage (IV)b
aMultimodal treatment includes computed tomography and/or RT.
bChemotherapy includes etoposide- and platinum-based regimens.
LCNECs, large-cell neuroendocrine carcinomas; RT, radiotherapy.
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IMMUNOHISTOCHEMISTRY
Pathologic diagnosis of NSCLC routinely uses a panel 
of immunohistochemical markers: cytokeratin (CK) 5/6, pro-
tein (p) 63, and p40 are squamous markers and thyroid tran-
scription factor-1, napsin A, and CK7 are adenocarcinoma 
markers, whereas chromogranin A, synaptophysin, and CD56 
are usually considered neuroendocrine markers. All the previ-
ous often are common to several lines of differentiation and 
may significantly overlap. Nevertheless, by using this panel 
of markers, an unspecific diagnosis of LCC could be better 
specified. Thus, approximately 60% to 70% of LCC can be 
reclassified as poorly differentiated adenocarcinoma, 10% to 
20% as squamous carcinoma, and 5% only as LCNEC.19
Regarding immunohistochemistry analysis, pulmonary 
LCNECs express typical neuroendocrine markers such as chro-
mogranin, neuron-specific enolase, synaptophysin, and soma-
tostatin, which are necessary to obtain the diagnosis, whereas 
they are negative for high-molecular-weight CKs, typically 
expressed by SCLC and other neuroendocrine tumors7 (Table 1).
Indeed, recent data show that LCNECs express higher 
levels of tropomyosin-related kinase B and brain-derived 
neurotrophic factor by immunohistochemistry than both non-
neuroendocrine tumor and SCLC23 although none of them is 
clearly enough to help in the differential diagnosis between 
LCNEC and the other pulmonary neuroendocrine tumors.
MOLECULAR MARKERS
Pulmonary LCNEC proliferative rate is higher than 
classic LCC and other low-grade neuroendocrine tumors, 
such as carcinoids. As SCLC, they show higher expression of 
Ki-67, Bcl-2, and p21 and of telomerase activity, abnormal 
p53, and absent Rb.24 In particular, Onuki et al.25 analyzed 
loss of heterozygosity (LOH) at 10 chromosomal regions 
and p53 mutations in 59 neuroendocrine tumors, including 
18 LCNEC. They found high frequencies of LOH and p53 
alterations in LCNEC (83% and 72%, respectively): p53 alter-
nations were in 23% LOH, 31% point mutations, and 46% 
both. Abnormalities of p53 seemed to be correlated to poor 
survival. These data derive from single, small-size retrospec-
tive studies, so it is impossible to obtain realistic recommen-
dations for clinical practice.
The bigger genomic-based classification of lung cancer 
produced by the Clinical Lung Cancer Genome Project and 
Network Genomic Medicine identified important similarities 
between LCNEC and SCLC, regarding also the transcriptome, 
amplified and deleted regions and mutated genes. Therefore, 
the authors suggest that to combine immunohistochemical 
and genomic analysis to differentiate each other.26
DIFFERENTIAL DIAGNOSIS BETWEEN SCLC 
AND PULMONARY LCNEC
SCLC and pulmonary LCNEC share several charac-
teristics such as high incidence in males and smokers, high 
mitotic rate, variable neuroendocrine marker expression, high 
grade, poor prognosis, and some genetic alterations (i.e., 
MEN1gene mutation). Indeed, these two histotypes are often 
combined in the single entity of high-grade neuroendocrine 
carcinoma (HGNEC).21
LCNEC can be distinguished from SCLC using some 
morphologic criteria: larger cell size, abundant cytoplasm, 
polygonal shape (versus fusiform), less evident nuclear mold-
ing, and less DNA deposits in blood vessels16 (Table 2).
Nitadori et al.27 found a stronger CK7, CK18, E-cadherin, 
and beta-catenin expression in pulmonary LCNEC as com-
pared with SCLC. However, despite the discrete body of evi-
dence and studies, more prospective data are necessary.
PROGNOSIS AND SURVIVAL
Pulmonary LCNEC behaves biologically aggressive, 
similarly to SCLC. Stage by stage, survival curves of pulmo-
nary LCNEC and SCLC overlap, and in addition, survival is 
lower than other NSCLCs. Prognosis is poor even in patients 
with potentially resectable stage I lung cancer with 5-year sur-
vival rates ranging from 27% to 67%.28
Regarding all stages, Iyoda et al.28,29 revealed a 5-year 
survival rate of 35.3% and a 5-year disease-free survival rate 
of 27.4% (Table 1); great part of relapses occurred within the 
first 2-year follow-up. One of the causes of this dramatic issue 
is the development of second primary cancers, synchronous 
or metachronous.
TREATMENT
There is no standard treatment of pulmonary LCNEC, 
and only few data are available primarily from case series. 
Because it is a very rare disease, randomized clinical trials are 
difficult to be conducted. Five-year OS remains poor, despite 
multimodal treatment in advanced stages and incidence of 
recurrence after surgery is high even in stage I disease.30
Surgical Management
Primary surgery should be the first option in oper-
able patients (TNM stages I and II). This approach consti-
tutes also the principal way to obtain an accurate diagnosis. 
Unfortunately, the majority of pulmonary LCNEC are not 
eligible for surgical resection because of local or systemic 
spread. Instead, in early stages, lobectomy or pneumonectomy 
are the preferred choices because they may improve survival 
in the absence of lymph node metastases at mediastinal sam-
pling30 (Table 1).
Grand et al.31 conducted a retrospective analysis to compare 
pulmonary LCNEC with LCC outcomes. They did not evidence 
any significant difference in terms of type of surgical approach 
(resection, lobectomy, or pneumonectomy) and OS. By contrast, 
they identified the rate of visceral pleura invasion as a frequent 
finding in combined LCNEC compared with pure LCNEC.
Mazières et al.32 reported a case series of 18 patients 
with pulmonary LCNEC treated with radical surgery, fol-
lowed by adjuvant radiotherapy in T3 and/or N2 cases. One-
year survival rate was 27%, and there was no correlation with 
nodal status.
Zacharias et al.30 suggested that an extended complete 
anatomical resection with a systematic nodal dissection may 
influence survival.
Definitely, surgery may be curative in approximately 
30% of cases; therefore, optimization of perioperative treat-
ments could improve outcome.
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Adjuvant Setting
All potentially resectable pulmonary LCNEC (stage 
I–III) should be operated.33 Perioperative, neoadjuvant,33 or 
adjuvant chemotherapeutic treatment could be valid options 
to prevent disease relapse.34
Indeed, a retrospective analysis of 144 surgically 
removed pulmonary LCNEC revealed a better outcome 
although not statistically significant, with preoperative or 
postoperative chemotherapy in stage I disease, suggesting that 
adjuvant therapy has a promising role in earliest diagnosed 
disease.35
The optimum regimen has not been established yet; 
moreover, it is not clear whether pulmonary LCNEC should 
be treated such as an SCLC.
In 2006, Iyoda et al.36 conducted a prospective single-
arm study of cisplatin–etoposide chemotherapy, the stan-
dard regimen for SCLC, as adjuvant treatment in completely 
resected pulmonary LCNEC comparing outcomes with his-
torical data of patients treated without platinum in the same 
institution. Five-year OS favored the study arm (88.9% versus 
47.4 %) and 2-year disease-free survival was 86.7% versus 
47.8%. Three years later, the same group confirmed the supe-
riority of platinum-based adjuvant chemotherapy over a non-
platinum adjuvant therapy or no adjuvant therapy. In addition, 
multivariate analysis showed that platinum-based adjuvant 
chemotherapy may have a significant impact on prognosis.28
More recently, a pilot adjuvant trial in HGNEC, includ-
ing pulmonary LCNEC, enrolled patients to receive three to 
four cycles of cisplatin–irinotecan chemotherapy, after cura-
tive surgery. This study showed 3-year relapse-free survival of 
74% and 3-year OS of 86%.37
On the basis of these studies, a phase III clinical trial 
of adjuvant cisplatin plus irinotecan versus etoposide has 
been designed and is still ongoing in Japan (Japan Clinical 
Oncology Group 1205/1206, UMIN000010298).38
Nevertheless, data presented are too much inadequate 
to provide a realistic recommendation because they all come 
from retrospective studies or studies having a too much little 
sample.
Currently, a defined biomarker of response to che-
motherapy has been not yet identified. Skov et al.39 stud-
ied the expression of ERCC1, a member of the nucleotide 
excision repair system, involved in the repair of platinum-
induced DNA damage and its correlation with chemosen-
sitivity in a small cohort of patients with neuroendocrine 
lung tumors (SCLC, TC, AC, and LCNEC). Although the 
authors found a different expression of ERCC1 among neu-
roendocrine tumors with higher levels in low-grade neuro-
endocrine tumors (79% of TC and 67% of AC) and lower 
levels in SCLC and LCNEC (19% of LCNEC and 10% of 
SCLC), this difference did not affected the median survival. 
Probably, the study population was too much little to gain 
significance.
Sarkaria et al.40 examined the role of neoadjuvant 
platinum-based chemotherapy in LCNEC, without identify-
ing a clear significance, but only a trend toward a better OS 
for patients treated with a multimodal treatment. Actually, it 
should not be used in such patients initially susceptible for 
surgery (Table 3).
The role of radiotherapy32 in the treatment of local 
or advanced pulmonary LCNEC is still unclear, but some 
authors suggest its use in locally advanced disease setting. 
Prophylactic cranial irradiation, which is largely used in lim-
ited disease SCLC after partial or complete response (CR) to 
chemotherapy, is not currently recommended in pulmonary 
LCNEC patients.
TABLE 2.  Differential Diagnosis between SCLC and Pulmonary LCNEC
Feature LCNEC SCLC
Incidence 2.%1–3.5% 15%–20%
Clinical features Male/smoker/older Male/smoker/older
Lung location Peripheral or midzone Central
Mitotic rate >11 mitoses/10 high power field >11 mitoses/10 high power field
Cytology Large cells Small cells
Abundant cytoplasm Scarce cytoplasm
Significant nuclear pleomorphism Significant nuclear pleomorphism
Prominent nucleoli No prominent nucleoli
Growth pattern Organoid, palisading Diffuse sheets of cells
Abundant necrosis Abundant necrosis
IHC Variable NE marker expression Variable neuroendocrine marker expression
Lymphatic metastases at diagnosis 60%–80% 60%–80%
Distant metastases at diagnosis 40% 60%–70%
Five-year survival 15%–25% <15%
Treatment Surgery and neoadjuvant or adjuvant chemotherapy  
and/or RT for early stages (I to II)
Surgery and concurrent CT and RT (stages I to II)
Chemotherapy and/or RT (stage III) Concurrent CT and RT (stage III)
Etoposide- and platinum-based regimens for stage IV Etoposide- and platinum-based regimens for stage IV
CT, computed tomography; SCLC, small-cell lung cancer; LCNEC, large-cell neuroendocrine carcinoma; RT, radiotherapy; IHC, immunohistochemistry.
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Metastatic Setting
There is not a consensus on standard treatment for recur-
rent or advanced LCNEC. Positive results with SCLC-based 
regimes in neoadjuvant and perioperative setting encouraged 
to use this strategy also in unresectable disease.32,36,37
In 2005, Rossi et al.41 analyzed 83 cases of pulmonary 
LCNEC (65% metastatic patients), exploring clinical and thera-
peutic histories and performing immunohistochemical screen-
ing of several receptor tyrosine kinases to identify new potential 
therapeutic targets and better strategies of treatment. Review 
of clinical features confirmed prevalence of male sex, strong 
smoker habitus, median-age incidence, and peripheral loca-
tion of lung lesion. Main sites of metastasization were brain, 
bone, and liver. Regarding chemotherapeutic strategies, their 
analysis confirmed in metastatic patients a greater efficacy of 
platinum–etoposide chemotherapy, with a response rate (RR) 
of 29%, including two cases of CRs and four partial responses 
(PRs); on the other hand, no CR or PR were observed in meta-
static patients treated with different chemotherapeutic schemes. 
Immunohistochemical evaluation of receptor tyrosine kinases 
expression revealed positivity of platelet-derived growth factor 
receptor-β (81.9%), platelet-derived growth factor receptor-α 
(60.2%), met-protoncogene receptor tyrosyne kinase (47%), 
v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homo-
log (62.7%), and stem cell factor (56.6%), which is c-KIT 
ligand always copresent with KIT. Interestingly, the only statis-
tical significant correlation was found between MET positivity 
and OS, with a median OS of 18 and 24 months in MET posi-
tive and negative, respectively.41
In 2007, Fujiwara et al.42 retrospectively analyzed out-
comes from pulmonary LCNEC patients (22 patients, of which 
20 were stage IIIB or IV or recurrent) receiving platinum plus 
irinotecan/taxanes/vinorelbine/etoposide or paclitaxel. PFS and 
objective response rate (ORR) on total patient population were 
4.1 months and 59.1%, respectively. More efficacious regimes 
were platinum–paclitaxel (ORR, 71.4%) and platinum–irinote-
can (ORR, 55.6%), with a median OS of 10.3 months and 1-year 
survival rate of 43%. All these results referred to a very small 
sample of patients: only four patients received platinum/etopo-
side, and survival of this subgroup was not reported.
Nevertheless, they are in agreement with those derived 
from the analysis of subgroups of LCNECs in previous stud-
ies.43–45 The efficacy of these drugs needs to be confirmed by 
prospective multi-institutional trials.
It is becoming increasingly evident that LCNEC tends 
to share several characteristics with SCLC also in terms of 
chemotherapy response,46,47 so efforts have been directed to 
clarify whether pulmonary LCNEC could be treated as SCLC, 
as NSCLC or as another variant of lung tumor.
Tokito et al.48 analyzed differences in treatment 
response to various schemes of chemotherapy of so called 
pulmonary “possible LCNEC.” The term “possible LCNEC” 
was introduced by Travis et al.47 referring to NSCLC posi-
tive to neuroendocrine markers and with neuroendocrine 
morphologic features on small samples derived from biop-
sies. He reviewed 24 “possible LCNEC” and 10 “defined 
LCNEC,” who underwent SCLC-like chemotherapy (plati-
num plus etoposide or irinotecan) in 67% and 60% of cases, 
respectively, finding no statistical differences in RR, PFS, 
or median survival time (median follow-up of 23.2 months). 
RR in “possible LCNEC” was 54%, similar to that obtained 
from previous analysis in the same setting: 50% by Igawa et 
al.46 and 61% by Shimada et al.49
Thus, considering that the clinical efficacy of chemo-
therapy for unresectable LCNEC has been shown to be com-
parable with that for extensive disease SCLC,46 new bigger 
and prospective trials for validation of SCLC-like approach 
both in defined and possible pulmonary LCNEC should be 
encouraged.
An interesting study on chemotherapy in pulmonary 
LCNEC patients has been published by Sun et al. 2 years ago.50 
They conducted a retrospective analysis on 45 pulmonary 
LCNEC patients treated with chemotherapy, stratifying them 
by SCLC therapy or standard NSCLC therapy and by sex, age, 
smoking habit, and neuroendocrine immunohistochemical 
pattern. The choice of chemotherapeutic strategy depended on 
oncologist decisions, so patients received different treatments: 
SCLC strategy was platinum–etoposide/irinotecan in 24.4% 
of patients and NSCLC strategy was platinum-based doublet 
(with gemcitabine, vinorelbine, pemetrexed, or taxanes) in 
68.9%; only one patient received vinorelbine–gemcitabine 
and two patients received a TKI. OS was 16.5 months versus 
9.2 months for SCLC-like treated patients versus NSCLC-like 
group, respectively. Median PFS was 6.1 versus 4.9 months, 
respectively. RR was 73% versus 50% for the two populations 
of treatment; interestingly, the best RR was obtained with plat-
inum-based regimens (60% overall, 41% when combined with 
gemcitabine, 7% to pemetrexed) compared with nonplatinum 
based (11%) and TKI (0%). Probably due to the small number 
of patients, these results were not statistically significant but 
underlined the importance to use platinum in first-line therapy 
for pulmonary LCNEC.
TABLE 3.  Adjuvant and Neoadjuvant Setting
Authors Study No. of Patients Treatment Survival p Value
Iyoda et al.36 Phase II, one-arm 
nonrandomized
15 Cisplatin plus VP-16 88.9% at 5 yr 0.0252
Iyoda et al.28 Multivariate analysis 79 Platinum based 88.7% at 5 yr <0.0001
Kenmotsu et al.37 Prospective phase II 23 Cisplatin plus irinotecan 86% at 3 yr 95% CI, 69%–95%
Sarkaria et al.40 Retrospective review of a 
prospective database
25 Platinum based (20 patients), 
Platinum/etoposide (15 patients)
51% at 5 yr 0.052
CI, confidence interval.
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Several reports investigated the activity of other thera-
peutic agents in advanced setting. Among whom, pemetrexed 
efficacy in pulmonary LCNEC was found to be very poor, and 
this evidence should be ascribed to the major levels of thy-
midylate synthase expressed by this histotype compared with 
other NSCLC subtypes.51,52 Taxanes seemed to be more active, 
similarly to SCLC.53 Instead, poor efficacy of TKI could be 
linked to the low percentage of EGFR-activating mutations in 
pulmonary LCNEC.54
In 2013, two multicenter phase II trials evaluated cispl-
atin-based combination chemotherapy in unresectable pulmo-
nary LCNEC.55,56
In the first one, conducted by Le Treut et al.,55 poor 
results on OS (8 months) were obtained with three to six 
cycles of cisplatin–etoposide chemotherapy in stage IIIB/IV 
LCNEC. It was a prospective, multicenter, single-arm, phase 
II study, with ORR as primary end point. Among 42 patients 
enrolled, only 29 diagnoses were centrally confirmed. In this 
subgroup stable disease occurred in 31% of patients, PR in 
34% and progression disease in 35%; median PFS was 5 
months and median OS was 8 months. All these results were 
not significantly different from total population and confirmed 
a worse prognosis.
In the second one, Niho et al.56 demonstrated that cispla-
tin–irinotecan could be an efficacious first-line chemotherapy 
option in stage IIIB or IV pulmonary LCNEC. Forty-four 
patients were enrolled in this single-arm study with RR as pri-
mary end point. Forty-one samples were centrally revised and 
reclassified as LCNEC (30 patients), SCLC (10 patients), and 
NSCLC with neuroendocrine structure (one patient). RR was 
46.7% for LCNEC reclassified patients versus 80% in the 10 
cases reclassified as SCLC. Median survival was 12.6 and 17.3 
months, respectively, suggesting not only a worse prognosis of 
LCNEC compared with SCLC but also a minor chemorespon-
siveness. Despite some limitations of this trial including sta-
tistical biases, small sample size (only 10 SCLC patients), and 
lack of information on second-line treatments, this is the first 
study that have evaluated prospectively this chemotherapeutic 
scheme in pulmonary LCNEC patients (Table 4) although it 
was as not designed to compare RR, PFS, and OS across dif-
ferent histology groups.
TREATMENT AFTER FIRST LINE
Options for second-line treatment of SCLC are regi-
mens including anthracyclines such as vinblastin, epirubicin/
adriablastin, and cysplatinum.
The most investigated drug in this setting is amrubicin, 
a synthetic topoisomerase II inhibitor, extensively investi-
gated in SCLC57 and currently approved for SCLC in Japan 
and not by U.S. Food and Drug Administration or European 
Medicines Agency.
In a retrospective revision, 18 LCNEC patients pre-
treated with platinum-based chemotherapy were treated from 
2002 to 2008 with amrubicin single agent in second (72%) 
or subsequent lines of therapy (28%), with promising results. 
ORR resulted of 27.7% (5 PR, with disease control rate dis-
ease control rate of 61%), PFS was 3.1 months, and OS of 5.1 
months58 (Table 3). Moreover, amrubicin treatment showed 
modest efficacy also in third/fourth lines of therapy.59
FUTURE DIRECTIONS
Few data are available on biological treatment in pul-
monary LCNEC. Rossi et al.41 in 2005 analyzed molecular 
profile of 83 LCNEC patients and the correlation with clinical 
outcome, identifying a significant correlation between MET 
TABLE 4.  Metastatic Setting
Authors Study Line
No. of  
Patients Treatment ORR (%) mPFS (mo) mOS (mo)
Fujiwara  
et al.42
Retrospective review First 22 Cisplatin + irinotecan (n = 9), 
platinum + paclitaxel (n = 6), 
paclitaxel alone (n = 1), 
cisplatin + vinorelbine (n = 1), 
cisplatin + docetaxel (n = 1), 
platinum + etoposide (n = 4)
59.1%; 55.6% 
with irinotecan; 
71.4% with 
paclitaxel (95% 
CI, 38.1–80.1)
4.1 (95% CI, 
3.1–5.1)
10.3 (95% CI, 
5.8–14.8). 10.3 
with paclitaxel or 
irinotecan (95% 
CI, 0–21.8)
Sun  
et al.50
Retrospective review First 45 SCLC regimen group: platinum 
+ etoposide (n = 11); NSCLC 
regimen group: platinum + 
taxanes/gemcitabine/ 
pemetrexed/vinorelbine or 
EGFR-TKIs (n = 34)
73% in SCLC 
group vs. 50% in 
NSCLC group 
(p = 0.19)
6.1 in SCLC 
group vs. 4.9 in 
NSCLC group 
(p = 0.41)
16.5 in SCLC 
group vs. 9.2 in 
NSCLC group 
(p = 0.10)
Le Treut  
et al.55
Prospective, 
multicenter, 
single- 
arm, phase II
First 29 Cisplatin + etoposide — 5.0 (95% CI, 
4.0–7.9)
8.0 (95% CI, 
3.7–7.9)
Niho  
et al.56
Prospective, 
multicenter, phase II
First 30 Cisplatin + irinotecan 46.7% (95% CI, 
28.3–65.7)
5.8 (95% CI, 
3.8–7.8)
12.6 (95% CI, 
9.3–16)
Yoshida  
et al.58
Retrospective review Second  
and/or s.s.
18 Amrubicin 27.7 (95% CI, 
9.7–53.5)
3.1 (95% CI, 
0.9–5.7)
5.1 (95% CI, 
2.2–9.7)
ORR, objective response rate; CI, confidence interval; SCLC, small-cell lung cancer; NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; TKIs, tyrosine 
kinase inhibitors; mPFS, median progression free survival; mOS, median overall survival; s.s., statistically significant.
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positivity and OS: median OS was 18 and 24 months in MET-
positive and MET-negative samples, respectively.
Recent reports describe the presence of EGFR-activating 
mutations, involving exons 19 or 21 in mixed LCNECs with 
an adenocarcinoma component, indicating that EGFR muta-
tions should be evaluated in this specific setting.60–63 Clinical 
responses to EGFR-targeted agent were, in fact, encouraging.
Angiogenesis is known to be one of the greater mecha-
nism of tumor evolution; therefore, an important role could 
be played by inhibition of angiogenesis pathways, such as 
vascular endothelial growth factor, signal transducer and acti-
vator of transcription 1, and signal transducer and activator 
of transcription 3.64 Recently, Mairinger et al.65 explored how 
angiogenesis could be involved in LCNEC metastasization, 
hypothesizing the use of anti–angiogenetic-targeted drugs in 
association with chemotherapy.
Data of literature demonstrated a correlation between 
lymphangiogenesis and angiogenesis and hypoxia-inducible 
factor 1-α expression, a transcription factor that in response 
to hypoxia induces genes responsible of angiogenesis.66,67 
In particular, overexpression of fibroblast growth factor and 
Fms-reLated Tyrosine kinase 4 and the reduced expression of 
Kinase insert Domain Receptor and hypoxia-inducible factor 
1-α seemed to predict a trend toward malignant behavior and 
worse outcome.65
New agents under clinical development include neda-
platin, a platinum-based antineoplastic drug, in combination 
with irinotecan68 (Table 4).
Other innovative therapeutic targets could be repre-
sented by tropomyosin-related kinase B and brain-derived 
neurotrophic factor that are highly expressed in LCNEC as 
markers of invasiveness.22
To date, further studies are still needed to confirm 
positive data on all these drugs and especially better explore 
their use in pulmonary LCNEC to obtain the maximum 
effectiveness.
DISCUSSION
LCNEC of the lung is a rare tumor with a poor progno-
sis; because of biological and molecular features, they should 
be ascribed to the category of grade III neuroendocrine LCC, 
part of the neuroendocrine spectrum of lung cancer.
Previous studies have reported poor outcomes for 
patients with LCNEC, with 5-year survival rates ranging from 
15% to 57%.7,8,20,23
Therefore, the prognosis of LCNEC patients has not 
changed. One of the main problems in the definition of the 
correct therapy is the lack of large phase II and III trials, 
which are very difficult to design and conduct because of the 
rarity of this tumor and the difficulties in the diagnosis. A way 
to overcome this issue may be the creation of large coopera-
tive groups, which can accumulate enough patients to study 
LCNEC prospectively.
Current standard treatment for early-stage patients 
is radical surgery. Adjuvant chemotherapy, even in stage I 
patients, has shown benefit although the optimal schedule is 
yet to define.28,48 Neoadjuvant platinum-based regimens may 
be a feasible option for potentially resectable tumors.37 Rossi 
et al.41 recently demonstrated the efficacy of cisplatin plus eto-
poside in the adjuvant setting. Nevertheless, all these studies 
are retrospective.
Observation of clinical behavior and several genetic 
studies69,70 showed that LCNEC is very similar to SCLC. 
Furthermore, Filosso et al.71 reported preliminary data on the 
role of octreotide as from adjuvant therapy in LCNEC of the 
lung.
Irinotecan plus cisplatin combination was shown to be 
acceptable and feasible as adjuvant chemotherapy for com-
pletely resected HGNEC.37 Thus, a randomized phase III 
trial is ongoing in Japan to evaluate this combination in com-
parison with etoposide and cisplatin, for completely resected 
HGNEC (Japan Clinical Oncology Group 1205/1206).
In the advanced disease setting, the RR to cisplatin-based 
combinations chemotherapy was 50% in a series of 20 patients.72 
Therefore, it is possible that a first-line NSCLC-like regimen 
should not be significantly inferior to an SCLC-like regimen.
Some reports showed the presence of EGFR-activating 
mutations in patients with pulmonary mixed LCNEC.60,63 It is 
common evidence that EGFR-TKIs are efficacious in tumors 
harboring an EGFR-activating mutation regardless of histol-
ogy. However, these mutations seem to be extremely rare in 
LCNEC-pure type, whereas they could be identified in the 
variant with adenomatous component.
Prophylactic cranial irradiation is a useful treatment 
modality for SCLC,73 but its role in LCNEC should be an 
object of future research.
In conclusion, given the rarity of the neoplasm in object 
and the difficulty in obtaining a reliable diagnosis, especially 
on small biopsies, it is hopeful to create a cooperation between 
different hospitals to discuss diagnosis and treatment strate-
gies and to conduct prospective randomized trials, with a 
number as larger as possible of patients.
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